Journal: Morbidity and Mortality Weekly Report
Article Title: Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
doi: 10.15585/mmwr.mm7501a2
Figure Lengend Snippet: Summary of vaccine studies, vaccine groups, immunogenicity timepoints, and safety follow-up included in the assessment of evidence for use of pentavalent (MenABCWY) vaccine — United States, 2025 * Saez-Llorens, 2015: https://doi.org/10.1080/21645515.2015.1029686 ; Block, 2015: https://doi.org/10.1016/j.vaccine.2015.03.001 ; Welsch, 2018: https://doi.org/10.1016/j.vaccine.2018.07.016 ; Vesikari, 2021: https://doi.org/10.1080/21645515.2021.1968214 ; Beran, 2021: https://doi.org/10.1128/mSphere.00553-21 ; GSK, 2024 (v72_72): https://clinicaltrials.gov/study/NCT04502693 ; GSK, 2024 (MenABCWY_019): https://clinicaltrials.gov/study/NCT04707391 . For the Beran (2021) study, the two vaccine groups with concomitant administration of MenACWY and MenB doses differed slightly; participants of one group received both doses in the same arm, whereas the other received each dose in a different arm. † Only vaccine groups considered in the evidence assessment are depicted. When multiple doses were administered, the per-protocol interval between doses is depicted. § Immunogenicity timepoints are the timepoints considered in the evidence assessment, not all protocol-specified timepoints at which immunogenicity was evaluated. ¶ Safety follow-up refers to the follow-up period for protocol-specified reporting of serious adverse events.
Article Snippet: A pentavalent (serogroups A, B, C, W, and Y) meningococcal vaccine (MenABCWY) (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer]) has been licensed and recommended for use since October 2023.
Techniques: Immunopeptidomics, Blocking Assay
